

ReNerve

ASX:RNV

Transforming Nerve Repair Through Science

Investor Update | June 2025

Berkeley Biologics Partnership (Announced 2 June 2025)



Important Notice & Disclaimer

Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation.

Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction.

Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision.

Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", "should", "could", "estimates", "target", "likely", "plan", "expects", "may", "intend", "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements.

Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice. An offer of Shares in ReNerve Ltd (ABN 23 614 848 216) is being made in or accompanied by a prospectus dated at a date to be confirmed. Anyone who wants to acquire Shares pursuant to the offer will need to complete the application form that accompanies the prospectus. A person should consider and rely only on the prospectus in deciding whether to invest. A copy of the prospectus is available by contacting the Company or by downloading from the Company's website (www.renerve.com.au).

Speculative nature of investment: Any potential investor should be aware that subscribing for Shares involves various risks. The Shares to be issued pursuant to the Prospectus lodged with ASIC by ReNerve Ltd carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those Shares. An investment in Shares of the Company should therefore be considered very speculative.

Executive Summary



Development of Novel Nerve Repair & Regenerative Tissue Products

ReNerve is focused on developing a portfolio of products for the nerve repair and regenerative tissue markets, with clearly defined commercial demand.



Significant Product Portfolio

ReNerve currently has one product in market with a clear commercial pathway for FDA approval of 5+ product ranges over the next 4 years.



Strong Sales & Distribution Presence

ReNerve have established logistics, warehouse and invoicing infrastructure with a growing sales distribution network able to sell all products.




Swift Global Expansion & Commercialisation

Successful ongoing expansion within the first year of listing into major surgical markets throughout Asia, The Middle East, and The Americas.



Clinical & Professional Validation

Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeons.



ReNerve's Opportunity

ReNerve Nerve Cuff



ReNerve Nerve Conduit



ReNerve Nerve Guide Matrix



ReNerve Bionic Nerve



Product	<ul style="list-style-type: none">Used on damaged or transected nerves with no gaps or gap closure	<ul style="list-style-type: none">Improved Nerve Cuff developed from scCO2 tissue, offering better product profile	<ul style="list-style-type: none">An ‘off-the-shelf’, ready to use nerve graft replacement with internal guidance infrastructure	<ul style="list-style-type: none">An ‘off-the-shelf’, continuous nerve replacement, in a ready to use nerve structure																						
Procedure Use	<ul style="list-style-type: none">End to end suturing covered with a wrap/cuffProtective cuff for grafts	<ul style="list-style-type: none">Protecting injured nerve repairs	<ul style="list-style-type: none">Replaces damaged nerve section instead of using donor or harvested tissue	<ul style="list-style-type: none">The Bionic Nerve is a nerve guide matrix with ionic polymers designed to replace injured and damaged nerves for lengths from 1cm to 20cm																						
Application	<ul style="list-style-type: none">TraumaBreast reconstructionOrthopedicsOral & maxillofacial surgery	<ul style="list-style-type: none">TraumaBreast reconstructionOrthopedicsFoot and ankle	<ul style="list-style-type: none">TraumaBreast reconstructionOrthopedicsHand & wrist	<ul style="list-style-type: none">TraumaCraniotomySpinal cord injurySpinal cord surgery																						
Benefit	<ul style="list-style-type: none">Bio-absorbed removing need for additional surgeryPliable and conforms	<ul style="list-style-type: none">Improved product profile to Nerve CuffStronger patient reimbursement	<ul style="list-style-type: none">Can be cut to ideal lengthOff-the-shelf, reducing logistics issuesSimple to use and cost effective	<ul style="list-style-type: none">Enable production of nerves of bespoke dimension																						
FDA Status	Approved	Targeting Q4 CY25 filing	Targeting Q2 CY27 filing	Targeting Q3 CY28 filing																						
TAM (USD)	<table><tr><th>Year</th><th>TAM (USD)</th></tr><tr><td>2024</td><td>\$314m</td></tr><tr><td>2030</td><td>\$975m</td></tr></table>	Year	TAM (USD)	2024	\$314m	2030	\$975m	<table><tr><th>Year</th><th>TAM (USD)</th></tr><tr><td>2024</td><td>\$1015m</td></tr><tr><td>2030</td><td>\$3219m</td></tr></table>	Year	TAM (USD)	2024	\$1015m	2030	\$3219m	<table><tr><th>Year</th><th>TAM (USD)</th></tr><tr><td>2024</td><td>\$635m</td></tr><tr><td>2030</td><td>\$1991m</td></tr></table>	Year	TAM (USD)	2024	\$635m	2030	\$1991m	<table><tr><th>Year</th><th>TAM (USD)</th></tr><tr><td>2023</td><td>>\$400m</td></tr></table>	Year	TAM (USD)	2023	>\$400m
Year	TAM (USD)																									
2024	\$314m																									
2030	\$975m																									
Year	TAM (USD)																									
2024	\$1015m																									
2030	\$3219m																									
Year	TAM (USD)																									
2024	\$635m																									
2030	\$1991m																									
Year	TAM (USD)																									
2023	>\$400m																									

The Berkeley Biologics Partnership

Why?


- Provides immediate products into the company portfolio and therefore sales.
- Products now approved for the US market.
- Stimulated by feedback from surgeons using the ReNerve nerve products.
- The new products are used by the same surgeons for related procedures.
- More common use than nerve repairs alone.

Synergies for ReNerve

- Produced through proprietary technology with strong science to the benefit of patients
- Two new complimentary product ranges
 - Dermal tissue product range.
 - Amniotic tissue ranges (three types of amniotic tissue products).
- Selling to the same target customers.
 - Orthopaedic, plastic and trauma surgery, breast reconstructions, etc.
- Selling through the same distribution channels and sales representatives.

Global Dermal & Amniotic Tissue Repair Markets

MarketWide Research – Dermal and Amniotic tissue market report 2025-2032, Published 2025.



ReNerve

**Dermal
product
range**



Key Features of Dermal Product Range



In Keeping with ReNerve Core Innovate Products

Produced using proprietary processes, whilst retaining physiological benefits.



Preserve Natural Matrix

Maintains structure like unprocessed dermis for improved tissue repair.



Porous Structure

Facilitates faster cell infiltration for improved healing outcomes.



Sterility-Assured and Room Temperature-Stored

Achieves high sterilisation while maintaining structurally-intact matrix.



Bioactive Components

Retains similar collagen integrity, mechanical strength, and bioactive properties.



Complimentary Product

The dermal tissue is used in procedures that existing ReNerve products are also already used in.

Key Benefits



Designed and processed to preserve the natural matrix as closely as possible to unprocessed dermis for optimal tissue repair and regeneration.




Closest to natural dermal tissue, compared to other dermal products¹.




Achieves high sterility-assurance levels, while maintaining a structurally-intact matrix that retains similar collagen integrity, mechanical strength, and bioactive components as the natural dermis.

1) Data on file

Unprocessed
Dermal Tissue



New ReNerve
Dermal Product



Natural Dermal Integrity is Preserved

ReNerve

**Amniotic
product
ranges**




Key Features of Amniotic Product Range




Highly Complimentary Products Used Across Procedures

Most nerve repairs are related to some type of wound and require some level of wound care – particularly in plastic, micro, orthopaedic and trauma surgery.



Ideal Wound Covering Options for Challenging Cases

- Natural barrier protects the wound during healing
- Easy to use and apply, with no rehydration needed
- Contains levels of growth factors and cytokines to benefit healing



Room Temperature-Stored

- Whilst achieving high sterilisation standards
- Synergistic to existing ReNerve products logistically



Three Amniotic Product Ranges

- Amniotic layer with chorion
- Amniotic layer with no chorion
- Bi-layer amniotic tissue

Partnership Highlights



In-Market Products

Gives ReNerve two new synergistic product ranges coming to market within months to build sales revenue



Diverse Product Portfolio

Expands the product portfolio with complimentary products and expands the addressable target markets for ReNerve



Immediate Market Need

The new products are used by surgeons with an immediate target market that is complimentary to the existing ReNerve business

Near Term Milestones – 2025

1H 2025

27 February 2025

Partnership Signed for Mexico Market

March 2025

Clinical Study Data

11 March 2025

Thailand Approval & First Hong Kong Sale

28 March 2025

Clinical Study Results Presented

10 April 2025

Partnership for Indian Market Announced

29 April 2025

Q3 FY25 Results: Revenue Growth & Clinical Validation

28 May 2025

NervAlign Nerve Cuff approved in Bahrain

2 June 2025

Partnership with Berkeley Biologics for new product ranges

2H 2025

Additional NervAlign® Nerve Cuff
Clinical Data

NervAlign® Nerve Conduit into Market
(Q4 2025)

Initial Clinical Cases for the
Nerve Conduit

First sales of the dermal
tissue product range

First sale of the amniotic
tissue product range

Near Term

Progression of the Nerve
Guide Matrix to Stage 3
of Development

H2 2025 (Estimated) –
India: Regulatory
Approval Pathway
Initiated

Content goes here

Content goes here

Investment Highlights



In Market Product

Anticipated 4 product ranges in market by the end of the year with the two new product ranges coming to market next quarter.




Immediate Market Need

Clear market need for all products especially given the strong science behind each product range



Growing Market

Nerve repair biomaterials market is forecasted to grow by >17% pa, estimated to be worth **>US\$6.19Bn by 2031**. Growing human tissue market which is synergistic to the nerve market



Diverse Product Portfolio

Now have three product ranges in the market and more coming



Growing Distribution

Continuing to build sales representation with a targeted-direct sales approach.



Board & Management

Highly accomplished executive team with a proven track record in the development & commercialisation of medical opportunities.

ReNerve

ASX:RNV

Contact

ReNerve Limited

📞 +61 (03) 9482 3940

✉ info@renerve.com.au

📍 Level 10/99 Queen St, Melbourne, Victoria 3000 Australia

